Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Niveditha Muralidharan"'
Autor:
Sunitha Kodidela, Patchava Dorababu, Dimpal N Thakkar, Biswajit Dubashi, Rajan Sundaram, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi, Suresh Chandra Pradhan, Chakradhara Rao Satyanarayana Uppugunduri
Publikováno v:
Genes, Vol 11, Iss 594, p 594 (2020)
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explo
Autor:
Sunitha, Kodidela, Patchava, Dorababu, Dimpal N, Thakkar, Biswajit, Dubashi, Rajan, Sundaram, Niveditha, Muralidharan, Ravi Prasad, Nidanapu, Anil, Aribandi, Suresh Chandra, Pradhan, Chakradhara Rao Satyanarayana, Uppugunduri
Publikováno v:
Genes
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explo
Autor:
Rajagopal Krishnamoorthy, Niveditha Muralidharan, Christina Mary Mariaselvam, Ryad Tamouza, Vir Singh Negi, Catherine Fortier, Durga Prasanna Misra, Dominique Charron
Publikováno v:
International Journal of Immunogenetics. 44:114-121
Summary Nitric oxide synthase (NOS) catalyses the production of nitric oxide (NO) from L-Arginine, which participates in diverse biological processes including inflammation and apoptosis. Macrophages, chondrocytes, osteoblasts and osteoclasts express
Publikováno v:
Clinical Rheumatology. 36:1253-1259
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease causing joint damage and significant functional impairment. Methotrexate (MTX) remains the mainstay for the treatment of RA. MTX inhibits several enzymes of the folate and nucleotide
Autor:
Vikramraj K Jain, Christina Mary Mariaselvam, Niveditha Muralidharan, Reena Gulati, Vir Singh Negi
Publikováno v:
Pharmacogenomics. 17:241-248
Aim: To find the association of ATIC 347C>G gene polymorphism with methotrexate (MTX) treatment response and MTX-induced adverse events in south Indian Tamil patients with rheumatoid arthritis. Patients & methods: A total of 319 rheumatoid arthritis
Autor:
Dimpal N Thakkar, Chakradhara Rao S. Uppugunduri, Rajan Sundaram, Suresh Chandra Pradhan, Sunitha Kodidela, Biswajit Dubashi, Patchava Dorababu, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi
Publikováno v:
Genes. 11:594
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explo
Autor:
Vir Singh Negi, Durga Prasanna Misra, Rajan Sundaram, Christina Mary Mariaselvam, K G Chengappa, Niveditha Muralidharan, Sunitha Kodidela
Publikováno v:
The pharmacogenomics journal. 20(2)
The aim of the study was to look for the association of FPGS 2752 G > A (rs1544105), FPGS 1994 A > G (rs10106), and GGH 452 C > T (rs 11545078), GGH −401C > T (rs 3758149) gene polymorphisms with methotrexate (MTX) treatment response and MTX-induce
Autor:
Vir Singh Negi, Niveditha Muralidharan, Paul T. Antony, Christina Mary Mariaselvam, Vikramraj K Jain
Publikováno v:
European Journal of Clinical Pharmacology. 71:959-965
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily targeting the synovial joints causing joint damage and significant functional impairment. Methotrexate (MTX) remains the mainstay for the treatment of RA, and approximately
Publikováno v:
Clinical and experimental medicine. 18(1)
The aim of the study was to look for any association of MTR 2756A>G and MTRR 66A>G gene polymorphisms with clinical phenotype, methotrexate (MTX) treatment response, and MTX-induced adverse events in South Indian Tamil patients with rheumatoid arthri
Publikováno v:
Clinical rheumatology. 35(4)
Methotrexate (MTX) is the most commonly used disease-modifying drug to treat rheumatoid arthritis (RA). Although there are no reliable molecular markers to predict the treatment response and adverse effects to MTX therapy, the polymorphisms in genes